Thomas David R, Penney Claire A, Majumder Amrita, Walmsley Amanda M
School of Biological Sciences, Monash University, Clayton, Victoria 3800, Australia; E-Mails:
Int J Mol Sci. 2011;12(5):3220-36. doi: 10.3390/ijms12053220. Epub 2011 May 17.
The science and policy of pharmaceuticals produced and/or delivered by plants has evolved over the past twenty-one years from a backyard remedy to regulated, purified products. After seemingly frozen at Phase I human clinical trials with six orally delivered plant-made vaccines not progressing past this stage over seven years, plant-made pharmaceuticals have made a breakthrough with several purified plant-based products advancing to Phase II trials and beyond. Though fraught with the usual difficulties of pharmaceutical development, pharmaceuticals made by plants have achieved pertinent milestones albeit slowly compared to other pharmaceutical production systems and are now at the cusp of reaching the consumer. Though the current economic climate begs for cautious investment as opposed to trail blazing, it is perhaps a good time to look to the future of plant-made pharmaceutical technology to assist in planning for future developments in order not to slow this technology's momentum. To encourage continued progress, we highlight the advances made so far by this technology, particularly the change in paradigms, comparing developmental timelines, and summarizing the current status and future possibilities of plant-made pharmaceuticals.
过去二十一年来，植物生产和/或提供的药物科学与政策已从一种民间疗法发展成为经过监管的纯化产品。在六种口服植物源疫苗进行了一期人体临床试验且似乎在七年多时间里一直停滞不前之后，植物源药物取得了突破，几种纯化的植物基产品进入了二期试验及更后期阶段。尽管植物源药物面临着药物研发中常见的困难，但与其他药物生产系统相比，其发展较为缓慢，不过还是实现了相关的里程碑，目前正处于即将面向消费者的阶段。尽管当前的经济形势要求谨慎投资而非开拓创新，但现在或许是展望植物源药物技术未来的好时机，以助力规划未来发展，以免减缓这项技术的发展势头。为鼓励持续进步，我们着重介绍了该技术迄今取得的进展，特别是范式的转变，比较了发展时间表，并总结了植物源药物的现状和未来可能性。
